Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma [0.03%]
局部可切除和潜在可切除胰腺导管腺癌的新辅助治疗进展
Gregory C Wilson,Sameer H Patel,Syed A Ahmad
Gregory C Wilson
Mortality after the diagnosis of pancreatic ductal adenocarcinoma remains high for all patients. The role of multimodal therapy, including surgical resection and systemic chemotherapy, has been well established. Neoadjuvant treatment strate...
Catherine S Valukas,Sunandana Chandra,Jaehyuk Choi et al.
Catherine S Valukas et al.
Merkel cell carcinoma is a rare, aggressive cutaneous neuroendocrine tumor, often diagnosed in later stages. Most of cases are related to either ultraviolet exposure or infection with the Merkel cell polyomavirus. Immunocompromised patients...
Dominic J Vitello,Jeffrey D Wayne
Dominic J Vitello
Gastrointestinal stromal tumors (GISTs) are rare neoplasms originating in the mesenchyme of the gastrointestinal tract. An evolving treatment paradigm in the management of GISTs is the usage of neoadjuvant therapy (NAT). Prior to undergoing...
Naaman Mehta,Amita Kulkarni,Katina Robison
Naaman Mehta
Gynecologic cancer treatments often lead to increased sexual concerns, which often are not addressed. Screening should be performed in a standardized fashion both routinely and frequently. Various treatment options are available and should ...
Allison Grubbs,Emma L Barber,Dario R Roque
Allison Grubbs
A significant amount of the literature on health disparities in gynecologic cancer care has focused on descriptively identifying disparities with a particular focus on the dichotomous care received by black and white patients. Although ther...
Emma C Rossi
Emma C Rossi
The surgical staging of endometrial cancer has changed in recent years to include sentinel lymph node (SLN) biopsy as a tool to replace regional lymphadenectomy. This has afforded surgeons the ability to preserve surgical staging informatio...
Advances in Cervical Cancer [0.03%]
宫颈癌的新进展
Olivia W Foley,Danielle Strom,Emily M Hinchcliff
Olivia W Foley
Cervical cancer continues to represent an immense burden worldwide. Fortunately, in all stages of the disease and therapeutic modalities there have been significant advances in the past 5 years with the promise of improving oncologic outcom...
McKenzie Foxall,Rebecca Arend
McKenzie Foxall
Gynecologic malignancies are a heterogenous group of tumors driven by a wide variety of molecular alterations. Molecular profiling has become increasingly useful in the development of novel biomarkers, screening tools, and targeted therapeu...
Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets [0.03%]
MAPK驱动的罕见妇科癌症及靶向治疗的新思路
Rachel N Grisham,Aaron Praiss,Chrisann Kyi et al.
Rachel N Grisham et al.
The mitogen-activated protein kinase (MAPK) cascade is a critical pathway involved in cancer cell survival as well as resistance to drug therapy. Phosphorylation of extracellular signal-regulated kinase 1 (ERK1) and extracellular signal-reg...
Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application [0.03%]
抗体药物偶联物治疗妇科肿瘤的研究进展及临床应用专家共识摘要
Mary Towner,Jenna Marcus
Mary Towner
Antibody-drug conjugates are a class of novel antineoplastic drugs that deliver potent cytotoxic agents directly into tumor cells by targeting tumor-specific antigens. Two of these drugs are currently approved for treatment of gynecologic c...